Debbie Osteen's Return Energizes Acadia Healthcare; Stock Climbs Over 21%

Acadia Healthcare Company, Inc. (ACHC) confirmed that Debbie Osteen will resume her role as Chief Executive Officer effective immediately, replacing Chris Hunter who has exited the company and resigned from its Board of Directors. The market responded positively to the announcement, with shares jumping over 21% to $14.20 in trading. Investors appear confident that Osteen’s return will steer the behavioral healthcare leader toward renewed growth and operational excellence.

Market Celebrates Leadership Transition

The significant stock rally reflects investor optimism surrounding Osteen’s appointment. As a former board member who previously led Acadia from December 2018 through March 2022 before serving as Director until 2024, Osteen brings proven track record and deep industry expertise. Reeve Waud, Chairman of the Board, praised the decision, noting that “Debbie is a mission-driven executive with a commitment to patients who helped transform Acadia into the leading provider of behavioral healthcare in the U.S.” Her return signals the Board’s confidence in revitalizing the company’s strategic direction.

Osteen’s Leadership Legacy and Strategic Vision

During Chris Hunter’s tenure, the company expanded its service capacity, developed new facilities through strategic joint venture partnerships, and invested significantly in its quality platform to enhance care delivery. Now with Osteen back at the helm, shareholders anticipate accelerated progress on these initiatives. Her previous leadership demonstrated the ability to balance operational growth with patient care quality—a combination that appears resonant with current market demands.

2025 Financial Outlook Remains Solid

Acadia maintained its 2025 financial guidance despite the leadership change. The company projects full-year revenue between $3.28 billion and $3.30 billion, with adjusted earnings per share ranging from $1.94 to $2.04. Additionally, the company expects Adjusted EBITDA for 2025 to fall between $601 million and $611 million. For reference, 2024 delivered total revenue of $3.15 billion, demonstrating consistent performance. Over the past year, ACHC stock traded within a range of $11.43 to $45.61, positioning the current level within the broader context of annual volatility. The stability of these forward-looking targets underscores management confidence under Osteen’s renewed leadership.